Indication

Treatment of moderate to severe active rheumatoid arthritis (RA) in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs (DMARDs). Filgotinib may be used as monotherapy or in combination with methotrexate. (MTX).

Medicine details

Medicine name:
filgotinib (Jyseleca)
SMC ID:
SMC2475
Pharmaceutical company
Galapagos Biotech Ltd
BNF chapter
Musculoskeletal and joint diseases
Submission type
Resubmission
Publication due date:
TBC
SMC meeting date:
TBC
Patient group submission deadline:
01 August 2022